Patent Grant
11033638
The present application is the 35 U.S.C. 371 National Stage of International Application Number PCT/EP2016/050147, filed Jan. 7, 2016, which claims priority from European patent application 15150376.0, filed Jan. 7, 2015, the contents of which are incorporated herein by reference,
A computer readable text file, entitled “031902-5028-US-Sequence-Listing.txt”, created on or about Jul. 5, 2017 with a file size of about 159 KB contains the sequence listing for this application and is hereby incorporated by reference in its entirety.
The invention pertains to the medical field, comprising gene therapy compositions for use in the treatment of Diabetes Type 1 (T1D), Diabetes Type 2 (T2D) and/or Monogenic Diabetes, either in higher mammals, particularly pets and more particularly dogs; or in human beings.
The two main forms of diabetes mellitus are type 1 (TID) and type 2 (T2D) (Diabetes care, 1997, 20-1183-1197). TED is characterized by a severe lack of insulin production due to specific destruction of the pancreatic β-cells. β-cell loss in TID is the result of an autoimmune mediated process, where a chronic inflammation called insulitis causes β-cell destruction (Eizirik D. L. et al, 2001, Diabetologia, 44:2115-2133 and Mathis D et al, 2001, Nature, 414: 792-798).
TID is one of the most common endocrine and metabolic conditions in childhood; incidence is rapidly increasing, especially among young children. TID is diagnosed when the autoimmune-mediated β-cell destruction is almost complete and patients need insulin-replacement therapy to survive. TID in an adult may present itself as T2D, with a slow deterioration in metabolic control, and subsequent progression to insulin dependency. This form is called latent autoimmune diabetes mellitus in adults (LADA) (Diabetes Atlas 4th edition, 2009, International Diabetes Federation).
Lifelong insulin treatment is the therapy of choice for TID. While lifelong treatment with exogenous insulin successfully manages diabetes, correct maintenance of a normoglycemic state can be challenging, Chronic hyperglycemia leads to severe microvascular (retinopathy and nephropathy), macrovascular (stroke, myocardial infarction), and neurological complications. These devastating complications can be prevented by normalization of blood glucose levels. Brittle diabetes is one example of a difficult-to-manage disease. Additionally, in many underdeveloped countries, especially in less privileged families, access to self-care tools and also to insulin is limited and this may lead to severe handicap and early death in diabetic children (Diabetes Atlas 4th edition, 2009, International Diabetes Federation, Beran D. et al 2006, Lancet, 368: 1689-1695, and Gale E. A., et al, 2006, Lancet, 368: 1626-1628). The most common cause of death in a child with diabetes, from a global perspective, is lack of access to insulin; thus the availability of a one-time gene therapy approach could make a difference in terms of prognosis when access to insulin is limited (Greenwood H. L. et al, 2006, PLoS Med 3. e381).
The reduction of hyperglycemia and maintenance of normoglycemia is a goal of any therapeutic approach to TID. The current therapy for most diabetic patients is based on regular subcutaneous injections of mixtures of soluble (short-acting) insulin and lente (long-acting) insulin preparations. Other therapeutical approaches include gene therapy, which would offer the potential advantage of an administration of a viral vector, which could ideally provide the necessary insulin through the lifetime of the diabetic subject. WO 2012/007458 discloses the generation of two viral vectors, one expressing the insulin gene and one expressing the glucokinase gene as a treatment of diabetes. However, there is still a need for an improved diabetes treatment wherein a lower dose of vector could be used, wherein a concomitant expression of each gene is provided in each transfected cell, wherein an attractive yield of the virus could be obtained and/or wherein potential induced side effects due to immunological properties of the capsid are lowered.
Therefore there is still a need for designing new treatments for diabetes which do not have all the drawbacks of existing treatments.
The inventors designed improved gene therapy strategies based on adeno-associated viral (AAV) vector-mediated insulin/glucokinase muscle gene transfer to counteract diabetic hyperglycemia, dual-gene viral constructs encoding insulin and glucokinase were generated to ensure concomitant expression of both transgenes in transduced muscle cells.
Generation of dual-gene vectors will also allow decreasing vector dose, which in turn, should result in reduced risk of capsid-triggered immunity or other toxicities. From a regulatory point of view, the use of a dual vector will greatly facilitate the development of the treatment. Moreover, the use of a dual vector will allow for a dramatic reduction in the cost of manufacturing of AAV vectors. However, the skilled person knows that such a dual vector due to its size may not always be produced in sufficient yields to be used in a therapeutic setting and may not always be found to ensure acceptable expression levels of both transgenes. All dual vectors tested in the experimental part could be produced at acceptable titers and were found to be able to ensure acceptable expression levels of both transgenes.
Therefore the generation of such AAV dual vectors that contain both the insulin and glucokinase transgenes and potentially have improved therapeutic efficacy is not routine for a person skilled in the art, as demonstrated in the experimental part.
Viral Expression Construct
In a first aspect there is provided a viral expression construct comprising the elements a) and b):
a) a nucleotide sequence encoding an insulin operably linked to a first promoter,
b) a nucleotide sequence encoding a glucokinase operably linked to a second promoter, and said viral expression construct comprises at least one of elements c), d) and e)
c) the first and the second promoters are positioned in reverse orientation within the expression construct,
d) the first and the second promoters are positioned in reverse orientation within the expression construct and are located adjacent to each other and
e) the first promoter is a CMV promoter, preferably a mini CMV promoter.
The definition of “viral expression construct”, “promoter”, “operatively linked” has been provided in the part of the description entitled “general definitions”. Within the context of the invention, elements a) and b) define the expression cassette of a viral expression construct of the invention as further explained in the part of the description entitled “general definitions”.
In the context of the invention, a nucleotide sequence encoding an insulin could be replaced by:
A preferred nucleotide sequence encoding an insulin has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:1. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”. SEQ ID NO:1 is a nucleotide sequence encoding human insulin. The nucleotide sequence encoding an insulin may be derived from any insulin gene, preferably from dog, human or rat; or a mutated insulin gene, or a codon optimized insulin gene, preferably from human, dog or rat as for example disclosed in WO 2012/007458 which is incorporated by reference in its entirety.
An insulin as used herein exerts at least a detectable level of an activity of an insulin as known to the skilled person. An activity of an insulin is the regulation of hyperglycemia. This could be assessed using any technique known to the skilled person or as was done in the experimental part.
In the context of the invention, a nucleotide sequence encoding a glucokinase could be replaced by:
A preferred nucleotide sequence encoding an insulin has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:2. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”. SEQ ID NO:2 is a nucleotide sequence encoding human glucokinase. The nucleotide sequence encoding a glucokinase may be derived from any glucokinase gene, preferably from human or rat; or a mutated glucokinase gene, or a codon optimized glucokinase gene, preferably from human or rat as for example disclosed in WO 2012/007458 which is incorporated by reference in its entirety.
A glucokinase as used herein exerts at least a detectable level of an activity of a glucokinase as known to the skilled person. An activity of a glucokinase is to phosphorylate glucose. This activity could be assessed using assays known to the skilled person.
In the context of the invention, a first promoter is a promoter which is operatively linked to the insulin nucleotide sequence defined above and a second promoter is a promoter which is operatively linked to the glucokinase nucleotide sequence defined above.
In one embodiment, the first and second promoters are different. It is therefore not excluded that the first and second promoters are identical. In one embodiment, both promoters are cell-specific and/or tissue-specific, preferably both promoters are specific for skeletal muscle.
A preferred first promoter is a CMV promoter (element e).
In the context of the invention, a nucleotide sequence of a CMV promoter could be replaced by a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: 3. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:3. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”.
A first promoter as used herein (especially when his sequence is defined has having a minimal identity percentage with a given SEQ ID NO) should exert at least an activity of a promoter as known to the skilled person. Please be referred to the part of the description entitled “general definitions” for a definition of such activity. Preferably a first promoter defined has having a minimal identity percentage with a given SEQ ID NO should control transcription of the nucleotide sequence it is operably linked thereto (i.e. a nucleotide sequence encoding an insulin for the first promoter) as assessed in an assay known to the skilled person. The same holds for a second promoter with a nucleotide sequence encoding a glucokinase).
Preferably said CMV promoter is used together with an intronic sequence. In this context an intronic sequence may be replaced by a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: 4. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:4. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”.
In a more preferred embodiment, a CMV promoter is a mini CMV promoter. In the context of the invention, a nucleotide sequence of a mini CMV promoter could be replaced by a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: 5. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:5. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”.
In an even more preferred embodiment, a nucleotide sequence of a mini CMV promoter comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: 24. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:24. Even more preferably, a nucleotide sequence a mini CMV promoter has at least 60% sequence identity or similarity with SEQ ID NO: 24 or at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:24 and has a length of 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 109, 110 nucleotides.
Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”.
In an embodiment, said mini CMV promoter may be used together with the intronic sequence defined above.
A preferred second promoter is a RSV promoter.
In the context of the invention, a nucleotide sequence of a RSV promoter could be replaced by a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: 6. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:6. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”.
Preferably said RSV promoter is used together with an intronic sequence. In this context an intronic sequence may be replaced by a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: 23. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:23. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained in the part of the description entitled “general definitions”.
In a preferred embodiment, the first and the second promoters are positioned in reverse orientation within the viral expression construct (element c). In this embodiment, it implies that the insulin and the glucokinase nucleotide sequences are read in opposite directions. More preferably, in this configuration, the first and the second promoters are adjacent to each other (element d). In this context, “adjacent” means that 0, 2, 5, 10, 20, 30, 50, 100, 200, 300, 400, 500, 600, 700 bases are present between the first and the second promoters.
Several viral expression constructs are therefore encompassed by the present invention:
A viral expression construct comprising elements a), b) and c),
A viral expression construct comprising elements a), b) and d),
A viral expression construct comprising elements a), b) and e),
A viral expression construct comprising elements a), b) and e), wherein the CMV promoter is a mini CMV promoter,
A viral expression construct comprising elements a), b), d) and e),
A viral expression construct comprising elements a), b), d) and e), wherein the CMV promoter is a mini CMV promoter.
For each of these preferred viral expression constructs defined above, the second promoter is preferably a RSV promoter as defined herein.
In an embodiment, a viral expression construct is encompassed comprising elements a) and b) and at least one of elements c), d) and e), wherein the first promoter is a CMV promoter, preferably a mini CMV promoter and/or wherein the second promoter is a RSV promoter.
Additional sequences may be present in the viral expression construct of the invention as explained in detail in the part of the description entitled “general definitions”. Preferred additional sequences include ITRs, SV40 (i.e. which means SV40 polyadenylation signal) (SEQ ID NO: 22), bGH (i.e. which means bGH polyadenylation signal) (SEQ ID NO:7), SV40 polyadenylation signal and enhancer sequence (SEQ ID NO:30), SV40 enhancer sequence (SEQ ID NO: 33). Within the context of the invention, “ITRs” is intended to encompass one 5′ITR and one 3′ITR, each being derived from the genome of a AAV. Preferred ITRs are from AAV2 and are represented by SEQ ID NO: 31 (5′ ITR) and SEQ ID NO: 32 (3′ ITR). Within the context of the invention, it is encompassed to use the SV40 enhancer sequence either included in the SV40 polyadenylation signal (as SEQ ID NO:30) or as a separate sequence (as SEQ ID NO:33). It is also encompassed to use the SV40 polyadenylation signal and the SV40 enhancer sequence as two separate sequences (SEQ ID NO:22 and SEQ ID NO: 33) or as a single sequence (SEQ ID NO:30).
Each of these additional sequences may be present in the viral expression construct of the invention (see for example as depicted in
In an embodiment, the viral expression construct comprising elements a) and b), and at least one of elements c), d) and e) as earlier defined and further comprises:
In a preferred embodiment, the viral expression construct comprising elements a) and b), and at least one of elements c), d) and e) as earlier defined and further comprises ITRs that flank the expression cassette of said construct and optionally
If the SV40 enhancer sequence is not included in the SV40 polyadenylation signal, the SV40 enhancer sequence is preferably located 5′ of the nucleotide sequence encoding the glucokinase or insulin.
These sequences were used in the experimental part in some of the constructs identified herein.
Therefore in one embodiment, for each of these preferred viral expression constructs defined above an additional sequence may be present selected from the group consisting of: ITRs, SV40 polyadenylation signal, bGH polyadenylation signal, SV40 polyadenylation signal and enhancer sequence, SV40 enhancer sequence.
In a preferred embodiment, a viral expression construct is encompassed comprising elements a) and b) and at least one of elements c), d) and e),
wherein the first promoter is a CMV promoter, preferably a mini CMV promoter and/or
wherein the second promoter is a RSV promoter and/or
wherein an additional sequence is present which is selected from the group consisting of: ITRs, SV40 polyadenylation signal, bGH polyadenylation signal, SV40 polyadenylation signal and enhancer sequence, SV40 enhancer sequence.
Preferred ITRs are those of AAV2 which are represented by SEQ ID NO: 31 (5′ ITR) and SEQ ID NO: 32 (3′ ITR).
Preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of elements c), d), e) is flanked by a 5′ITR and a 3′ITR.
Other preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of c), d), e) is flanked by a 5′ITR and a 3′ITR. In addition, SV40 polyadenylation signals are present.
Other preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of c), d), e) is flanked by a 5′ITR and a 3′ITR. In addition, SV40 and bGH polyadenylation signals are present.
Other preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of c), d), e) is flanked by a 5′ITR and a 3′ITR. In addition, SV40 enhancer sequence is present. Other preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of c), d), e) is flanked by a 5′ITR and a 3′ITR. In addition, SV40 enhancer sequence and SV40 polyadenylation signals are present as two separate sequences.
Other preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of c), d), e) is flanked by a 5′ITR and a 3′ITR. In addition, SV40 enhancer sequence and SV40 polyadenylation signals are present as two separate sequences. In this embodiment, bGH polyadenylation signals are also present.
Other preferred viral expression constructs comprise elements a) and b) and at least one of elements c), d) and e) and are such that the expression cassette as defined by elements a), b) and at least one of c), d), e) is flanked by a 5′ITR and a 3′ITR. In addition, SV40 polyadenylation signals and enhancer sequence are present together with bGH polyadenylation signals are present.
Most preferred designed viral expression constructs include:
Construct A (represented by a nucleotide sequence comprising SEQ ID NO: 8),
Construct D (represented by a nucleotide sequence comprising SEQ ID NO: 9),
Construct E (represented by a nucleotide sequence comprising SEQ ID NO: 10),
Construct F (represented by a nucleotide sequence comprising SEQ ID NO: 11),
Construct G (represented by a nucleotide sequence comprising SEQ ID NO: 12),
Construct J (represented by a nucleotide sequence comprising SEQ ID NO: 13),
Construct K (represented by a nucleotide sequence comprising SEQ ID NO: 14),
Construct L (represented by a nucleotide sequence comprising SEQ ID NO: 15),
Construct M (represented by a nucleotide sequence comprising SEQ ID NO: 16).
Construct Q (represented by a nucleotide sequence comprising SEQ ID NO: 27).
Construct S (represented by a nucleotide sequence comprising SEQ ID NO: 29).
As the skilled person will understand, each of these viral expression constructs already comprise two ITRs from AAV2 (i.e. SEQ ID NO: 31 (5′ ITR) and SEQ ID NO: 32 (3′ ITR)).
Best results were obtained with constructs F (SEQ ID NO: 11), construct J (SEQ ID NO: 13), construct K (SEQ ID NO: 14), construct L (SEQ ID NO: 15), construct M (SEQ ID NO: 16), construct Q (SEQ ID NO: 27) and construct S (SEQ ID NO: 29).
Constructs L and Q comprise both bGH polyadenylation signal and SV40 polyadenylation signal sequences, the order of each of these 3′untranslated sequences being interchanged (see
Construct S comprises both bGH polyadenylation signal and SV40 polyadenylation signal and enhancer sequences (see
As explained in the general part entitled “general definitions”, throughout this application, each time one refers to a specific nucleotide sequence SEQ ID NO (take SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 27, 29) representing the preferred constructs designed herein, one may replace it by:
Each nucleotide sequence described herein by virtue of its identity percentage (at least 60%) with a given nucleotide sequence respectively has in a further preferred embodiment an identity of at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identity with the given nucleotide respectively. In a preferred embodiment, sequence identity is determined by comparing the whole length of the sequences as identified herein. Unless otherwise indicated herein, identity with a given SEQ ID NO means identity or similarity based on the full length of said sequence (i.e. over its whole length or as a whole).
A construct defined by its minimum identity (i.e. at least 60%) to a given SEQ ID NO as identified above is encompassed within the scope of the invention when this construct or a viral expression construct or a viral vector comprising this construct or a composition comprising this construct or vector is able to induce the expression of insulin and glucokinase in a cell, preferably in a muscle cell. The expression of both genes could be assessed using techniques known to the skilled person. In a preferred embodiment, said expression is assessed as carried out in the experimental part.
In a preferred embodiment, a viral expression construct is such that the construct is represented by a nucleotide sequence comprising SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 27 or 29 or a sequence having at least 60% identity with SEQ ID NO: 8, 9, 10, 11, 12, 13, 14, 15, 16, 27 or 29.
Viral Vector
In a further aspect, there is provided a viral vector. A viral vector comprises a viral expression construct as defined above. A viral vector is further defined in the part of the description entitled “general definitions”. Preferably a viral vector is a retrovirus vector, an adenovirus vector, an adeno-associated virus vector, a herpesvirus vector, a polyoma virus vector or a vaccinia virus vector. More detail is also provided in the part of the description entitled “general definitions”.
In an embodiment, an adeno-associated viral vector is used comprising each of the elements defined earlier herein and a rAAV based genome comprising inverted terminal repeats (ITR) or a part thereof. Preferred ITRs are those of AAV2 which are represented by SEQ ID NO: 31 (5′ ITR) and SEQ ID NO: 32 (3′ ITR).
Preferably, said adeno-associated viral vector is an adeno-associated virus vector, more preferably an AAV1 vector.
A viral expression construct and a viral vector of the invention are preferably for use as a medicament. The medicament is preferably for preventing, delaying, curing, reverting and/or treating a diabetes. Diabetes may be Diabetes Type 1, Diabetes Type 2 or Monogenic Diabetes. The subject treated may be a higher mammal, e.g. cats, rodent, (preferably mice, rats, gerbils and guinea pigs, and more preferably mice and rats), or dogs, or in human beings.
Composition
In a further aspect there is provided a composition comprising a viral expression construct or a viral vector as defined earlier herein. This composition is preferably called a gene therapy composition. Preferably, the composition is a pharmaceutical composition said pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant, diluents, solubilizer, filler, preservative and/or excipient.
Such pharmaceutically acceptable carrier, filler, preservative, solubilizer, diluent and/or excipient may for instance be found in Remington: The Science and Practice of Pharmacy, 20th Edition. Baltimore, Md.: Lippincott Williams & Wilkins, 2000.
In a preferred embodiment, said composition is for use as a medicament, preferably for preventing, delaying, curing, reverting and/or treating a diabetes. Diabetes may be Diabetes Type 1, Diabetes Type 2 or Monogenic Diabetes. The subject treated may be a higher mammal, e.g. cats, rodent, (preferably mice, rats, gerbils and guinea pigs, and more preferably mice and rats), or dogs, or in human beings.
Said viral expression construct, viral vector and/or composition are preferably said to be able to be used for preventing, delaying, reverting, curing and/or treating a diabetes, when said viral expression construct, viral vector and/or composition are able to exhibit an anti-diabetes effect. An anti-diabetes effect may be reached when glucose disposal in blood is increased and/or when glucose tolerance is improved. This could be assessed using techniques known to the skilled person or as done in the experimental part. In this context, “increase” (respectively “improvement”) means at least a detectable increase (respectively a detectable improvement) using an assay known to the skilled person or using assays as carried out in the experimental part.
An anti-diabetes effect may also be observed when the progression of a typical symptom (i.e. insulitis, beta cell loss, . . . ) has been slowed down as assessed by a physician. A decrease of a typical symptom may mean a slow down in progression of symptom development or a complete disappearance of symptoms. Symptoms, and thus also a decrease in symptoms, can be assessed using a variety of methods, to a large extent the same methods as used in diagnosis of diabetes, including clinical examination and routine laboratory tests. Such methods include both macroscopic and microscopic methods, as well as molecular methods, X-rays, biochemical, immunohistochemical and others.
A medicament as defined herein (viral expression construct, viral vector, composition) is preferably able to alleviate one symptom or one characteristic of a patient or of a cell, tissue or organ of said patient if after at least one week, one month, six month, one year or more of treatment using a viral expression vector or a composition of the invention, said symptom or characteristic is no longer detectable.
A viral expression construct or a viral vector or a composition as defined herein for use according to the invention may be suitable for administration to a cell, tissue and/or an organ in vivo of individuals affected by or at risk of developing a diabetes, and may be administered in vivo, ex vivo or in vitro. Said combination and/or composition may be directly or indirectly administrated to a cell, tissue and/or an organ in vivo of an individual affected by or at risk of developing a diabetes, and may be administered directly or indirectly in vivo, ex vivo or in vitro. A preferred administration mode is intramuscular.
A viral expression construct or a viral vector or a composition of the invention may be directly or indirectly administered using suitable means known in the art. Improvements in means for providing an individual or a cell, tissue, organ of said individual with a viral expression construct or a viral vector or a composition of the invention are anticipated, considering the progress that has already thus far been achieved. Such future improvements may of course be incorporated to achieve the mentioned effect of the invention. A viral expression construct or a viral vector or a composition can be delivered as is to an individual, a cell, tissue or organ of said individual. Depending on the disease or condition, a cell, tissue or organ of said individual may be as earlier defined herein. When administering a viral expression construct or a viral vector or a composition of the invention, it is preferred that such viral expression construct or vector or composition is dissolved in a solution that is compatible with the delivery method. For intravenous, subcutaneous, intramuscular, intrathecal, intraarticular and/or intraventricular administration it is preferred that the solution is a physiological salt solution. Intramuscular administration is a preferred administration mode. More preferably intramuscular administration is carried out using a multineedle. As encompassed herein, a therapeutically effective dose of a viral expression construct, vector or composition as mentioned above is preferably administered in a single and unique dose hence avoiding repeated periodical administration. More preferably, the single dose is administered to muscle tissue, and even more preferably by means of a unique multi-needle injection.
A further compound may be present in a composition of the invention. Said compound may help in delivery of the composition. Below is provided a list of suitable compounds: compounds capable of forming complexes, nanoparticles, micelles and/or liposomes that deliver each constituent as defined herein, complexed or trapped in a vesicle or liposome through a cell membrane. Many of these compounds are known in the art. Suitable compounds comprise polyethylenimine (PEI), or similar cationic polymers, including polypropyleneimine or polyethylenimine copolymers (PECs) and derivatives, synthetic amphiphiles (SAINT-18), Lipofectin™, DOTAP.
Depending on their identity, the skilled person will know which type of formulation is the most appropriate for the composition, as defined herein.
In this context a further compound may be insulin that could be regularly injected.
Method/Use
In a further aspect there is provided a method for preventing, delaying, reverting, curing and/or treating a diabetes wherein a viral expression construct or viral vector or composition as defined herein as defined herein is being used.
Such a method is preferably for alleviating one or more symptom(s) of diabetes in an individual, in a cell, tissue or organ of said individual or alleviate one or more characteristic(s) or symptom(s) of a cell, tissue or organ of said individual, the method comprising administering to said individual a viral expression construct or viral vector or a composition as defined herein.
In a further aspect there is provided a use of a viral expression construct or viral vector or a composition as defined herein for the manufacture of a medicament for preventing, delaying, reverting, curing and/or treating a diabetes.
Diabetes and the type of subject treated have been earlier defined herein.
In one embodiment said method or use is performed in vitro, for instance using a cell culture. Preferably, said method or use is in vivo. Each feature of these methods/uses has already been defined herein. In a method of the invention, a viral expression construct or vector and/or a composition may be combined with an additional compound known to be used for treating diabetes in an individual.
In a preferred embodiment, a treatment in a use or in a method according to the invention does not have to be repeated. Alternatively in a use or a method according to the invention said administration of the viral expression construct or of said composition may be repeated each year or each 2, 3, 4, 5, 6 years.
Identity/Similarity
In the context of the invention, a protein or a protein fragment as insulin or glucokinase is represented by an amino acid sequence.
In the context of the invention, a nucleic acid molecule as a nucleic acid molecule encoding an insulin or a nucleic acid molecule encoding a glucokinase is represented by a nucleic acid or nucleotide sequence which encodes a protein or a polypeptide or a protein fragment or a peptide or a derived peptide. A nucleic acid molecule may comprise a regulatory region.
It is to be understood that each nucleic acid molecule or protein or protein fragment or peptide or derived peptide or polypeptide or construct as identified herein by a given Sequence Identity Number (SEQ ID NO) is not limited to this specific sequence as disclosed. Each gene sequence or nucleotide sequence or nucleic acid sequence as identified herein encoding a given protein or polypeptide or construct or protein fragment or peptide or derived peptide or is itself a protein or a protein fragment or polypeptide or construct or peptide or derived peptide. Throughout this application, each time one refers to a specific nucleotide sequence SEQ ID NO (take SEQ ID NO: X as example) encoding a given polypeptide, one may replace it by:
Throughout this application, each time one refers to a specific amino acid sequence SEQ ID NO (take SEQ ID NO: Y as example), one may replace it by: a polypeptide comprising an amino acid sequence that has at least 60% sequence identity or similarity with amino acid sequence SEQ ID NO: Y.
Each nucleotide sequence or amino acid sequence described herein by virtue of its identity or similarity percentage (at least 60%) with a given nucleotide sequence or amino acid sequence respectively has in a further preferred embodiment an identity or a similarity of at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or more identity or similarity with the given nucleotide or amino acid sequence respectively. In a preferred embodiment, sequence identity or similarity is determined by comparing the whole length of the sequences as identified herein. Unless otherwise indicated herein, identity or similarity with a given SEQ ID NO means identity or similarity based on the full length of said sequence (i.e. over its whole length or as a whole).
Each non-coding nucleotide sequence (i.e. of a promoter or of another regulatory region) could be replaced by a nucleotide sequence comprising a nucleotide sequence that has at least 60% sequence identity or similarity with SEQ ID NO: A. A preferred nucleotide sequence has at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 100% identity with SEQ ID NO:A. Identity may be assessed over the whole SEQ ID NO or over part thereof as explained herein. In a preferred embodiment, such non-coding nucleotide sequence such as a promoter exhibits or exerts at least an activity of such a non-coding nucleotide sequence such as an activity of a promoter as known to the skilled person.
“Sequence identity” is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. In a preferred embodiment, sequence identity is calculated based on the full length of two given SEQ ID NO or on part thereof. Part thereof preferably means at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% of both SEQ ID NO. In the art, “identity” also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
“Similarity” between two amino acid sequences is determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. “Identity” and “similarity” can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heine, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48:1073 (1988).
Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the GCG program package (Devereux, J., et al., Nucleic Acids Research 12 (1): 387 (1984)), BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215:403-410 (1990). The well-known Smith Waterman algorithm may also be used to determine identity.
Preferred parameters for polypeptide sequence comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992); Gap Penalty: 12; and Gap Length Penalty: 4. A program useful with these parameters is publicly available as the “Ogap” program from Genetics Computer Group, located in Madison, Wis. The aforementioned parameters are the default parameters for amino acid comparisons (along with no penalty for end gaps).
Preferred parameters for nucleic acid comparison include the following: Algorithm: Needleman and Wunsch, J. Mol. Biol. 48:443-453 (1970); Comparison matrix: matches=+10, mismatch=0; Gap Penalty: 50; Gap Length Penalty: 3. Available as the Gap program from Genetics Computer Group, located in Madison, Wis. Given above are the default parameters for nucleic acid comparisons.
Optionally, in determining the degree of amino acid similarity, the skilled person may also take into account so-called “conservative” amino acid substitutions, as will be clear to the skilled person. Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine. Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. Preferably, the amino acid change is conservative. Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to Ser; Arg to Lys; Asn to Gln or His; Asp to Glu; Cys to Ser or Ala; Gln to Asn; Glu to Asp; Gly to Pro; His to Asn or Gln; Ile to Leu or Val; Leu to Ile or Val; Lys to Arg; Gln or Glu; Met to Leu or Ile; Phe to Met, Leu or Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp or Phe; and, Val to Ile or Leu.
Gene or Coding Sequence
“Gene” or “coding sequence” or “nucleic acid” or “nucleic” refers to a DNA or RNA region (the transcribed region) which “encodes” a particular protein such as an insulin or a glucokinase. A coding sequence is transcribed (DNA) and translated (RNA) into a polypeptide when placed under the control of an appropriate regulatory region, such as a promoter. A gene may comprise several operably linked fragments, such as a promoter, a 5′ leader sequence, an intron, a coding sequence and a 3′nontranslated sequence, comprising a polyadenylation site or a signal sequence. A chimeric or recombinant gene (such as a chimeric insulin gene or a chimeric glucokinase gene) is a gene not normally found in nature, such as a gene in which for example the promoter is not associated in nature with part or all of the transcribed DNA region. “Expression of a gene” refers to the process wherein a gene is transcribed into an RNA and/or translated into an active protein.
Promoter
As used herein, the term “promoter” refers to a nucleic acid fragment that functions to control the transcription of one or more genes (or coding sequence), located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate the amount of transcription from the promoter. A “constitutive” promoter is a promoter that is active under most physiological and developmental conditions. An “inducible” promoter is a promoter that is regulated depending on physiological or developmental conditions. A “tissue specific” promoter is preferentially active in specific types of differentiated cells/tissues, such as preferably a muscle cell or tissue derived therefrom.
Operably Linked
“Operably linked” is defined herein as a configuration in which a control sequence such as a promoter sequence or regulating sequence is appropriately placed at a position relative to the nucleotide sequence of interest, preferably coding for an insulin or a glucokinase such that the promoter or control or regulating sequence directs or affects the transcription and/or production or expression of the nucleotide sequence of interest, preferably encoding an insulin or a glucokinase in a cell and/or in a subject. For instance, a promoter is operably linked to a coding sequence if the promoter is able to initiate or regulate the transcription or expression of a coding sequence, in which case the coding sequence should be understood as being “under the control of” the promoter. When one or more nucleotide sequences and/or elements comprised within a construct are defined herein to be “configured to be operably linked to an optional nucleotide sequence of interest”, said nucleotide sequences and/or elements are understood to be configured within said construct in such a way that these nucleotide sequences and/or elements are all operably linked to said nucleotide sequence of interest once said nucleotide sequence of interest is present in said construct.
Viral Expression Construct
An expression construct carries a genome that is able to stabilize and remain episomal in a cell. Within the context of the invention, a cell may mean to encompass a cell used to make the construct or a cell wherein the construct will be administered. Alternatively a construct is capable of integrating into a cell's genome, e.g. through homologous recombination or otherwise. A particularly preferred expression construct is one wherein a nucleotide sequence encoding an insulin and a glucokinase as defined herein, is operably linked to a first and a second promoters as defined herein wherein said promoters are capable of directing expression of said nucleotide sequences (i.e. coding sequences) in a cell. Such a preferred expression construct is said to comprise an expression cassette. An expression cassette as used herein comprises or consists of a nucleotide sequence encoding an insulin and an nucleotide sequence encoding a glucokinase, each of them being operably linked to a promoter (i.e. a first and a second promoter) wherein said promoters are capable of directing expression of said nucleotide sequences. A viral expression construct is an expression construct which is intended to be used in gene therapy. It is designed to comprise part of a viral genome as later defined herein.
Expression constructs disclosed herein could be prepared using recombinant techniques in which nucleotide sequences encoding said insulin and glucokinased are expressed in a suitable cell, e.g. cultured cells or cells of a multicellular organism, such as described in Ausubel et al., “Current Protocols in Molecular Biology”, Greene Publishing and Wiley-Interscience, New York (1987) and in Sambrook and Russell (2001, supra); both of which are incorporated herein by reference in their entirety. Also see, Kunkel (1985) Proc. Natl. Acad. Sci. 82:488 (describing site directed mutagenesis) and Roberts et al. (1987) Nature 328:731-734 or Wells, J. A., et al. (1985) Gene 34: 315 (describing cassette mutagenesis).
Typically, a nucleic acid or nucleotide sequence encoding an insulin and a glucokinase are used in an expression construct or expression vector. The phrase “expression vector” generally refers to a nucleotide sequence that is capable of effecting expression of a gene in a host compatible with such sequences. These expression vectors typically include at least suitable promoter sequences and optionally, transcription termination signals. An additional factor necessary or helpful in effecting expression can also be used as described herein. A nucleic acid or DNA or nucleotide sequence encoding an insulin and a glucokinase is incorporated into a DNA construct capable of introduction into and expression in an in vitro cell culture. Specifically, a DNA construct is suitable for replication in a prokaryotic host, such as bacteria, e.g., E. coli, or can be introduced into a cultured mammalian, plant, insect, (e.g., Sf9), yeast, fungi or other eukaryotic cell lines.
A DNA construct prepared for introduction into a particular host may include a replication system recognized by the host, an intended DNA segment encoding a desired polypeptide, and transcriptional and translational initiation and termination regulatory sequences operably linked to the polypeptide-encoding segment. The term “operably linked” has already been defined herein. For example, a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence. DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of a polypeptide. Generally, a DNA sequence that is operably linked are contiguous, and, in the case of a signal sequence, both contiguous and in reading frame. However, enhancers need not be contiguous with a coding sequence whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof, or by gene synthesis.
The selection of an appropriate promoter sequence generally depends upon the host cell selected for the expression of a DNA segment. Examples of suitable promoter sequences include prokaryotic, and eukaryotic promoters well known in the art (see, e.g. Sambrook and Russell, 2001, supra). A transcriptional regulatory sequence typically includes a heterologous enhancer or promoter that is recognised by the host. The selection of an appropriate promoter depends upon the host, but promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters are known and available (see, e.g. Sambrook and Russell, 2001, supra). An expression vector includes the replication system and transcriptional and translational regulatory sequences together with the insertion site for the polypeptide encoding segment can be employed. In most cases, the replication system is only functional in the cell that is used to make the vector (bacterial cell as E. Coli). Most plasmids and vectors do not replicate in the cells infected with the vector. Examples of workable combinations of cell lines and expression vectors are described in Sambrook and Russell (2001, supra) and in Metzger et al. (1988) Nature 334: 31-36. For example, suitable expression vectors can be expressed in, yeast, e.g. S. cerevisiae, e.g., insect cells, e.g., Sf9 cells, mammalian cells, e.g., CHO cells and bacterial cells, e.g., E. coli. A cell may thus be a prokaryotic or eukaryotic host cell. A cell may be a cell that is suitable for culture in liquid or on solid media.
Alternatively, a host cell is a cell that is part of a multicellular organism such as a transgenic plant or animal.
Viral Vector
A viral vector or a gene therapy vector is a vector that comprises a viral expression construct as defined above.
A viral vector or a gene therapy vector is a vector that is suitable for gene therapy. Vectors that are suitable for gene therapy are described in Anderson 1998, Nature 392: 25-30; Walther and Stein, 2000, Drugs 60: 249-71; Kay et al., 2001, Nat. Med. 7: 33-40; Russell, 2000, J. Gen. Virol. 81: 2573-604; Amado and Chen, 1999, Science 285: 674-6; Federico, 1999, Curr. Opin. Biotechnol. 10: 448-53; Vigna and Naldini, 2000, J. Gene Med. 2: 308-16; Marin et al., 1997, Mol. Med. Today 3: 396-403; Peng and Russell, 1999, Curr. Opin. Biotechnol. 10: 454-7; Sommerfelt, 1999, J. Gen. Virol. 80: 3049-64; Reiser, 2000, Gene Ther. 7: 910-3; and references cited therein.
A particularly suitable gene therapy vector includes an Adenoviral and Adeno-associated virus (AAV) vector. These vectors infect a wide number of dividing and non-dividing cell types including synovial cells and liver cells. The episomal nature of the adenoviral and AAV vectors after cell entry makes these vectors suited for therapeutic applications. (Russell, 2000, J. Gen. Virol. 81: 2573-2604; Goncalves, 2005, Virol J. 2(1):43) as indicated above. AAV vectors are even more preferred since they are known to result in very stable long term expression of transgene expression (up to 9 years in dog (Niemeyer et al, Blood. 2009 Jan. 22; 113(4):797-806) and ˜2 years in human (Nathwani et al, N Engl J Med. 2011 Dec. 22; 365(25):2357-65, Simonelli et al, Mol Ther. 2010 March; 18(3):643-50. Epub 2009 Dec. 1.)). Preferred adenoviral vectors are modified to reduce the host response as reviewed by Russell (2000, supra). Method for gene therapy using AAV vectors are described by Wang et al., 2005, J Gene Med. March 9 (Epub ahead of print), Mandel et al., 2004, Curr Opin Mol Ther. 6(5):482-90, and Martin et a, 2004, Eye 18(11):1049-55, Nathwani et al, N Engl J Med. 2011 Dec. 22; 365(25):2357-65, Apparailly et al, Hum Gene Ther. 2005 April; 16(4):426-34.
Another suitable gene therapy vector includes a retroviral vector. A preferred retroviral vector for application in the present invention is a lentiviral based expression construct. Lentiviral vectors have the ability to infect and to stably integrate into the genome of dividing and non-dividing cells (Amado and Chen, 1999 Science 285: 674-6). Methods for the construction and use of lentiviral based expression constructs are described in U.S. Pat. Nos. 6,165,782, 6,207,455, 6,218,181, 6,277,633 and 6,323,031 and in Federico (1999, Curr Opin Biotechnol 10: 448-53) and Vigna et al. (2000, J Gene Med 2000; 2: 308-16).
Other suitable gene therapy vectors include a herpes virus vector, a polyoma virus vector or a vaccinia virus vector.
A gene therapy vector comprises a nucleotide sequence encoding an insulin and a glucokinase to be expressed, whereby each of said nucleotide sequence is operably linked to the appropriate regulatory sequences. Such regulatory sequence will at least comprise a promoter sequence. Suitable promoters for expression of a nucleotide sequence encoding an insulin and a glycokinase from gene therapy vectors include e.g. cytomegalovirus (CMV) intermediate early promoter, viral long terminal repeat promoters (LTRs), such as those from murine moloney leukaemia virus (MMLV) rous sarcoma virus, or HTLV-1, the simian virus 40 (SV 40) early promoter and the herpes simplex virus thymidine kinase promoter. Suitable promoters are described below.
Several inducible promoter systems have been described that may be induced by the administration of small organic or inorganic compounds. Such inducible promoters include those controlled by heavy metals, such as the metallothionine promoter (Brinster et al. 1982 Nature 296: 39-42; Mayo et al. 1982 Cell 29: 99-108), RU-486 (a progesterone antagonist) (Wang et al. 1994 Proc. Natl. Acad. Sci. USA 91: 8180-8184), steroids (Mader and White, 1993 Proc. Natl. Acad. Sci. USA 90: 5603-5607), tetracycline (Gossen and Bujard 1992 Proc. Natl. Acad. Sci. USA 89: 5547-5551; U.S. Pat. No. 5,464,758; Furth et al. 1994 Proc. Natl. Acad. Sci. USA 91: 9302-9306; Howe et al. 1995 J. Biol. Chem. 270: 14168-14174; Resnitzky et al. 1994 Mol. Cell. Biol. 14: 1669-1679; Shockett et al. 1995 Proc. Natl. Acad. Sci. USA 92: 6522-6526) and the tTAER system that is based on the multi-chimeric transactivator composed of a tetR polypeptide, as activation domain of VP16, and a ligand binding domain of an estrogen receptor (Yee et al., 2002, U.S. Pat. No. 6,432,705).
A gene therapy vector may optionally comprise a further nucleotide sequence coding for a further polypeptide. A further polypeptide may be a (selectable) marker polypeptide that allows for the identification, selection and/or screening for cells containing the expression construct. Suitable marker proteins for this purpose are e.g. the fluorescent protein GFP, and the selectable marker genes HSV thymidine kinase (for selection on HAT medium), bacterial hygromycin B phosphotransferase (for selection on hygromycin B), Tn5 aminoglycoside phosphotransferase (for selection on G418), and dihydrofolate reductase (DHFR) (for selection on methotrexate), CD20, the low affinity nerve growth factor gene. Sources for obtaining these marker genes and methods for their use are provided in Sambrook and Russel (2001) “Molecular Cloning: A Laboratory Manual (3rd edition), Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, New York.
A gene therapy vector is preferably formulated in a pharmaceutical composition as defined herein. In this context, a pharmaceutical composition may comprise a suitable pharmaceutical carrier as earlier defined herein.
Adeno-Associated Virus Vector (AAV Vector)
A preferred viral vector or a preferred gene therapy vector is an AAV vector. An AAV vector as used herein preferably comprises a recombinant AAV vector (rAAV). A “rAAV vector” as used herein refers to a recombinant vector comprising part of an AAV genome encapsidated in a protein shell of capsid protein derived from an AAV serotype as explained herein. Part of an AAV genome may contain the inverted terminal repeats (ITR) derived from an adeno-associated virus serotype, such as AAV1, AAV2, AAV3, AAV4, AAV5 and others. Preferred ITRs are those of AAV2 which are represented by SEQ ID NO: 31 (5′ ITR) and SEQ ID NO: 32 (3′ ITR).
Protein shell comprised of capsid protein may be derived from an AAV serotype such as AAV1, 2, 3, 4, 5 and others. A preferred AAV capsid is a AAV1 capsid. A preferred ITR is from the AAV2. A protein shell may also be named a capsid protein shell. rAAV vector may have one or preferably all wild type AAV genes deleted, but may still comprise functional ITR nucleic acid sequences. Functional ITR sequences are necessary for the replication, rescue and packaging of AAV virions. The ITR sequences may be wild type sequences or may have at least 80%, 85%, 90%, 95, or 100% sequence identity with wild type sequences or may be altered by for example in insertion, mutation, deletion or substitution of nucleotides, as long as they remain functional. In this context, functionality refers to the ability to direct packaging of the genome into the capsid shell and then allow for expression in the host cell to be infected or target cell. In the context of the present invention a capsid protein shell may be of a different serotype than the rAAV vector genome ITR.
A nucleic acid molecule represented by a nucleic acid sequence of choice is preferably inserted between the rAAV genome or ITR sequences as identified above, for example an expression construct comprising an expression regulatory element operably linked to a coding sequence and a 3′ termination sequence. Said nucleic acid molecule may also be called a transgene.
“AAV helper functions” generally refers to the corresponding AAV functions required for rAAV replication and packaging supplied to the rAAV vector in trans. AAV helper functions complement the AAV functions which are missing in the rAAV vector, but they lack AAV ITRs (which are provided by the rAAV vector genome). AAV helper functions include the two major ORFs of AAV, namely the rep coding region and the cap coding region or functional substantially identical sequences thereof. Rep and Cap regions are well known in the art, see e.g. Chiorini et al. (1999, J. of Virology, Vol 73(2): 1309-1319) or U.S. Pat. No. 5,139,941, incorporated herein by reference. The AAV helper functions can be supplied on a AAV helper construct. Introduction of the helper construct into the host cell can occur e.g. by transformation, transfection, or transduction prior to or concurrently with the introduction of the rAAV genome present in the rAAV vector as identified herein. The AAV helper constructs of the invention may thus be chosen such that they produce the desired combination of serotypes for the rAAV vector's capsid protein shell on the one hand and for the rAAV genome present in said rAAV vector replication and packaging on the other hand.
“AAV helper virus” provides additional functions required for AAV replication and packaging. Suitable AAV helper viruses include adenoviruses, herpes simplex viruses (such as HSV types 1 and 2) and vaccinia viruses. The additional functions provided by the helper virus can also be introduced into the host cell via vectors, as described in U.S. Pat. No. 6,531,456 incorporated herein by reference.
A “transgene” is herein defined as a gene or a nucleic acid molecule (i.e. a molecule encoding an insulin and a molecule encoding a glucokinase) that has been newly introduced into a cell, i.e. a gene that may be present but may normally not be expressed or expressed at an insufficient level in a cell. In this context, “insufficient” means that although said insulin and glucokinase is expressed in a cell, a condition and/or disease as defined herein could still be developed. In this case, the invention allows the over-expression of an insulin and a glucokinase. The transgene may comprise sequences that are native to the cell, sequences that naturally do not occur in the cell and it may comprise combinations of both. A transgene may contain sequences coding for an insulin and a glucokinase and/or additional proteins as earlier identified herein that may be operably linked to appropriate regulatory sequences for expression of the sequences coding for an insulin and a glucokinase in the cell. Preferably, the transgene is not integrated into the host cell's genome.
“Transduction” refers to the delivery of an insulin and a glucokinase into a recipient host cell by a viral vector. For example, transduction of a target cell by a rAAV vector of the invention leads to transfer of the rAAV genome contained in that vector into the transduced cell. “Host cell” or “target cell” refers to the cell into which the DNA delivery takes place, such as the muscle cells of a subject. AAV vectors are able to transduce both dividing and non-dividing cells.
Production of an AAV Vector
The recombinant AAV vector, including all combinations of AAV serotype capsid and AAV genome ITRs, is produced using methods known in the art, as described in Pan et al. (J. of Virology 1999, Vol 73(4):3410-3417) and Clark et al. (Human Gene Therapy, 1999, 10:1031-1039), incorporated herein by reference. In short, the methods generally involve (a) the introduction of the rAAV genome into a host cell, (b) the introduction of an AAV helper construct into the host cell, wherein the helper construct comprises the viral functions missing from the rAAV genome and (c) introducing a helper virus into the host cell. All functions for rAAV vector replication and packaging need to be present, to achieve replication and packaging of the rAAV genome into rAAV vectors. The introduction into the host cell can be carried out using standard virological techniques and can be simultaneously or sequentially. Finally, the host cells are cultured to produce rAAV vectors and are purified using standard techniques such as CsCl gradients (Xiao et al. 1996, J. Virol. 70: 8098-8108). Residual helper virus activity can be inactivated using known methods, such as for example heat inactivation. The purified rAAV vector is then ready for use in the methods. High titres of more than 1012 particles per ml and high purity (free of detectable helper and wild type viruses) can be achieved (Clark et al. supra and Flotte et al. 1995, Gene Ther. 2: 29-37).
The rAAV genome present in a rAAV vector comprises at least the nucleotide sequences of the inverted terminal repeat regions (ITR) of one of the AAV serotypes (preferably the ones of serotype AAV2 as disclosed earlier herein), or nucleotide sequences substantially identical thereto or nucleotide sequences having at least 60% identity thereto, and nucleotide sequence encoding an insulin and a glucokinase (under control of a suitable regulatory element) inserted between the two ITRs. A vector genome requires the use of flanking 5′ and a 3′ ITR sequences to allow for efficient packaging of the vector genome into the rAAV capsid.
The complete genome of several AAV serotypes and corresponding ITR has been sequenced (Chiorini et al. 1999, J. of Virology Vol. 73, No. 2, p 1309-1319). They can be either cloned or made by chemical synthesis as known in the art, using for example an oligonucleotide synthesizer as supplied e.g. by Applied Biosystems Inc. (Fosters, Calif., USA) or by standard molecular biology techniques. The ITRs can be cloned from the AAV viral genome or excised from a vector comprising the AAV ITRs. The ITR nucleotide sequences can be either ligated at either end to the nucleotide sequence encoding one or more therapeutic proteins using standard molecular biology techniques, or the wild type AAV sequence between the ITRs can be replaced with the desired nucleotide sequence.
Preferably, the rAAV genome as present in a rAAV vector does not comprise any nucleotide sequences encoding viral proteins, such as the rep (replication) or cap (capsid) genes of AAV. This rAAV genome may further comprise a marker or reporter gene, such as a gene for example encoding an antibiotic resistance gene, a fluorescent protein (e.g. gfp) or a gene encoding a chemically, enzymatically or otherwise detectable and/or selectable product (e.g. lacZ, aph, etc.) known in the art.
The rAAV genome as present in said rAAV vector further comprises a promoter sequence operably linked to the nucleotide sequence encoding an insulin and a glucokinased. Preferred promoter sequences are promoters which confer expression in muscle cells and/or muscle tissues. Examples of such promoters include a CMV and a RSV promoters as earlier defined herein.
A suitable 3′ untranslated sequence may also be operably linked to the nucleotide sequence encoding an insulin and a glucokinase. Suitable 3′ untranslated regions may be those naturally associated with the nucleotide sequence or may be derived from different genes, such as for example the bovine growth hormone 3′ untranslated region (bGH polyadenylation signal (SEQ ID NO:7), SV40 polyadenylation signal (SEQ ID NO:22), SV40 polyadenylation signal and enhancer sequence (SEQ ID NO: 30).
Within the context of the invention, when one refers to “SV40”, it means SV40 polyadenylation signal. When one refers to “SV40 enhancer sequence”, it means SV40 polyadenylation signal and enhancer sequence. However, the invention also encompasses the use of SV40 polyadenylation signal (SEQ ID NO:22) and SV40 enhancer sequence (SEQ ID NO:33) as two separate sequences.
These sequences were used in the preferred constructs prepared in the experimental part. Constructs L and Q comprise both bGH polyA and SV40 polyadenylation signal sequences, the order of each of these 3′untranslated sequences being interchanged (see
Construct S comprises both bGH polyA and SV40 polyadenylation signal and enhancer sequences (see
Optionally, additional nucleotide sequences may be operably linked to the nucleotide sequence(s) encoding an insulin and a glucokinase, such as nucleotide sequences encoding signal sequences, nuclear localization signals, expression enhancers, and the like.
In this document and in its claims, the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition the verb “to consist” may be replaced by “to consist essentially of” meaning that a viral expression construct, viral vector, composition, gene therapy composition, as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention.
In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”.
The word “approximately” or “about” when used in association with a numerical value (approximately 10, about 10) preferably means that the value may be the given value of 10 more or less 1% of the value.
All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety. In this context WO 2012/007458 is incorporated by reference in its entirety. Each embodiment as identified herein may be combined together unless otherwise indicated.
The invention is further explained in the following examples. These examples do not limit the scope of the invention, but merely serve to clarify the invention.
Construct A: RSV-rGck-CMV-hIns (size: 4.9 kb) (SEQ ID NO: 8) is depicted in
Construct B is depicted in
Construct C is depicted in
Construct D is depicted in
Construct E is depicted in
Construct F is depicted in
Construct G is depicted in
Construct H is depicted in
Construct I is depicted in
Construct J is depicted in
Construct K is depicted in
Construct L is depicted in
Construct M is depicted in
Construct N is depicted in
Construct I is depicted in
Construct O is depicted in
Construct P is depicted in
Construct Q is depicted in
Construct R is depicted in
Construct S is depicted in
Throughout the application, one refers to constructs or vectors based on/comprising constructs A to S. The letter identifies the type of construct used and the same letter could be used to refer to a vector based on/derived from and/or comprising said construct. This is the reason why the ITRs are present in each of the
A. Generation of Dual-Gene Adeno-Associated Viral (AAV) Vector Constructs for the Concomitant Expression of Insulin and Glucokinase
In order to develop more effective gene therapy strategies based on adeno-associated viral vector-mediated insulin/glucokinase muscle gene transfer to counteract diabetic hyperglycemia, dual-gene viral constructs encoding insulin and glucokinase were generated to ensure concomitant expression of both transgenes in transduced muscle cells.
Generation of dual-gene AAV1-Ins+Gck vectors will also allow decreasing vector dose, which in turn, should result in reduced risk of capsid-triggered immunity or other toxicities. From a regulatory point of view, the use of a dual vector will greatly facilitate the development of the treatment. Moreover, the use of a dual vector will allow for a dramatic reduction in the cost of manufacturing of AAV vectors.
The generation of such AAV dual vectors that contain both the insulin and glucokinase transgenes and potentially have improved therapeutic efficacy is not, however, entirely routine for a person skilled in the art, as demonstrated below.
In the experimental part, the nucleotide sequence encoding insulin was SEQ ID NO:1, the nucleotide sequence encoding glucokinase was SEQ ID NO:2. The nucleotide sequence of the CMV promoter was SEQ ID NO: 3 used with associated intronic sequence SEQ ID NO:4. The nucleotide sequence of the RSV promoter was SEQ ID NO: 6 with associated intronic sequence SEQ ID NO:23. The nucleotide sequence of the mini CMV promoter was SEQ ID NO:5. The nucleotide sequence of the bGH regulatory region was SEQ ID NO: 7. The nucleotide sequence of the SV40 was SEQ ID NO: 22.
A.1. Dual-Gene AAV-CMV-Insulin-CMV-Glucokinase Construct
In the therapeutic approach that utilized 2 different AAV1 vectors to mediate the gene transfer to the skeletal muscle of the insulin and glucokinase genes when administered to mice and dogs (Mas, A. et al., Diabetes (2006) 55:1546-1553; Callejas, D. et al. Diabetes (2013) 62:1718-1729), the expression of both transgenes was driven by the CMV promoter. Therefore, the most obvious option to be considered while generating the dual-gene AAV constructs would have been to use CMV-Insulin and CMV-Glucokinase expression cassettes within the same vector. However, this option was discarded because the presence of the same promoter in 2 regions within the same construct increases dramatically the high risk of intramolecular recombination events that are sometimes observed during AAV production due to the presence of repeated sequences.
A.2. Dual-Gene CMV-Insulin-RSV-Glucokinase AAV Constructs
Taking into account the restrictions on the use of promoters discussed above, the ubiquitous Rous Sarcoma Virus (RSV) promoter was chosen to drive expression of glucokinase in the dual-gene AAV construct. This promoter was selected because, similar to the CMV promoter, it has been reported to mediate strong transgene expression in muscle cells (Yue Y. et al, 2002, Biotechniques, 33:672, p 676 Development of Multiple Cloning Site cis-Vectors for Recombinant Adeno-Associated Virus Production). Additionally, its small size is convenient given the limited cloning capacity of AAV vectors.
A dual-gene AAV1-Ins+Gck construct bearing the human insulin coding sequence driven by the CMV promoter and the rat glucokinase coding sequence driven by the RSV promoter (
Construct A: RSV-rGck-CMV-hIns (size: 4.9 kb) (SEQ ID NO: 8) is depicted in
In addition to the previously described dual-gene AAV1-Ins+Gck construct, two additional single-gene plasmids encoding either human insulin or rat glucokinase were generated, using the same AAV backbone (
Construct B is depicted in
Construct C is depicted in
The function of the dual-gene plasmid RSV-rGck-CMV-hIns (construct A) was assessed in vitro before AAV production and insulin and glucokinase were expressed at very high levels (
Having verified the functionality of the RSV-rGck-CMV-hIns (construct A) in vitro, the plasmid was used to produce the corresponding dual-gene AAV1 vector in HEK293 cells. The yield of the vector batch was, however, low. The first production of AAV1-RSV-rGck-CMV-hIns rendered no AAV vectors and the yield of the second production run was 4E11 viral genomes (vg)/roller bottle (RB), considerably lower than our in house average yield for AAV1 production (expected yield: 2E12 vg/RB). The final size of the AAV constructs was close to the limit of encapsidation capacity of the AAV1, and the observation of low yields could be consistent with the low efficiency of encapsidation of oversized genomes. Nevertheless, this result was not foreseeable because in some cases AAV constructs of approximately 5 kb have been successfully produced by our lab.
A.3. Optimized CMV-Insulin-RSV-Glucokinase Dual-Gene AAV Constructs
Given the relative low yield of the AAV batches produced with the previous dual-gene AAV constructs, we decided to completely remake the dual insulin and glucokinase expression cassettes. To this end, we designed a novel modular system that allowed us the test different combinations of coding sequences (optimized or not, and from different species) and cis-acting sequences (promoters, polyAs) at minimum effort and within optimal size for encapsidation. This new approached greatly simplified vector design.
First, we generated 4 additional dual-gene constructs containing the human insulin coding sequence under the control of the CMV promoter and the human glucokinase coding sequence driven by the RSV promoter. We tested the effect of positioning the insulin expression cassette upstream of the glucokinase expression cassette and viceversa, and also in reverse orientation (
In addition, in this new set of constructs, the CMV-hInsulin cassette included the SV40 polyA sequence whereas the bovine growth hormone polyA sequence was cloned in the RSV-hGlucokinase cassette, as the latter is shorter and mediates higher transgene expression than the SV40 polyA (Azzoni A R, J Gene Med. 2007: The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression). The new constructs are:
Construct D is depicted in
Construct E is depicted in
Construct F is depicted in
Construct G is depicted in
In addition to the aforementioned 4 dual-gene AAV1-Ins+Gck constructs (constructs D, E, F and G)), two additional single-gene plasmids encoding either insulin or glucokinase were generated using the same AAV backbone (
Construct H is depicted in
Construct I is depicted in
We assessed the function of the dual-gene constructs D, E, F and G plasmids in vitro in HEK293 cells and the F construct (CMV-hIns(rev)-RSV-rGck) mediated the highest insulin and glucokinase expression (
A.4. Optimized miniCMV-Insulin-RSV-Glucokinase Dual-Gene AAV Constructs
Given that the AAV1-CMV-hIns(rev)-RSV-hGck production rendered a relative low yield, we decided to further decrease the size of the dual-gene construct replacing the CMV promoter by a short version of such promoter, named mini CMV promoter. We generated 4 new dual-gene constructs bearing the human insulin coding sequence under the control of the mini CMV promoter and the human glucokinase coding sequence driven by the RSV promoter. The SV40 and the bGH polyA were used as polyA sequences, respectively. Again, we tested the effect of positioning the insulin expression cassette upstream of the glucokinase expression cassette or viceversa, and also the effect of positioning it the glucokinase expression cassette in reverse orientation (
Construct J is depicted in
Construct K is depicted in
Construct L is depicted in
Construct M is depicted in
In addition to these 4 new dual-gene AAV1-Ins+Gck constructs (J, K, L and M), an additional single-gene plasmid encoding insulin was generated using the same AAV backbone for comparison with the 4 new dual-gene AAV1-Ins+Gck constructs. The single-gene plasmid encoding Gck was the previously mentioned RSV-hGCK (construct I) (
Construct N is depicted in
Construct I is depicted in
We assessed the function of constructs J, K, L and M dual-gene plasmids in vitro in HEK293 cells and the (L) construct, miniCMV-hIns(rev)-RSV-hGck, mediated the highest expression of insulin and glucokinase (
This (L) construct (miniCMV-hIns(rev)-RSV-hGck) and the same construct (J) but in sense orientation (miniCMV-hIns-RSV-hGck dual-promoter) were used to produce the corresponding dual-gene AAV1 vectors in HEK293 cells.
In these cases, AAV production yields were within the expected value, being 2.1E12 vg/RB for AAV1-miniCMV-hIns(rev)-RSV-hGck (construct L) and 1.9E12 vg/RB for AAV1-miniCMV-hIns-RSV-hGck (construct J).
B. Increased Transgene Expression and Efficacy of Dual-Gene AAV1-miniCMV-hIns(rev)-RSV-hGck Vectors
B.1. Increased Transgene Expression In Vivo
To verify if the administration of the double-gene AAV1-Ins+Gck vectors was superior than the co-delivery of two single-gene AAV vectors in mediating the expression of insulin and/or glucokinase and/or in the ability to improve glucose disposal in response to a glucose overload, an in vivo experiment was performed in mice.
Two groups of wild type mice were treated with either the 2 single vectors together (constructs N+I) (AAV1-miniCMV-hINS and AAV1-RSV-hGck) or with the dual gene (construct L) (AAV1-miniCMV-hINS-rev-RSV-hGck). Vectors were administered intramuscularly into tibialis and gastrocnemius muscles of both hindlimbs at a dose of 5E10 vg/muscle of each vector (constructs N and I or L).
Three weeks after vector administration, animals were sacrificed and the expression of both transgenes (insulin and glucokinase) was analysed by real time quantitative PCR in the different experimental groups. We observed that the expression of both Insulin (
B.2. Increased Efficacy In Vivo
To demonstrate the efficacy of the newly designed dual-gene constructs, the ability of the vector to enhance glucose disposal in vivo was assessed in the previous described experimental groups. To this end, a glucose tolerance test was performed in which all groups of mice were injected intraperitoneally with 2 g glucose/kg body weight, and blood glucose levels were determined at different time points.
As observed in
B.3. Increased Efficacy In Vivo in Diabetic Mice
In order to assess efficacy of the dual-gene (construct L) vector (AAV1-miniCMV-hIns(rev)-RSV-hGck) in diabetic animals, a dose of 5E10 vg/muscle was administered intramuscularly into tibialis and gastrocnemius muscles of both hindlimbs of mice treated with streptozotocin (STZ) to trigger the diabetic process. As control, the 2 single vectors were administered together (construct N+I) (AAV1-miniCMV-hINS and AAV1-RSV-hGck).
Eight weeks post-AAV administration, a glucose tolerance test was performed in which all groups of mice were injected intraperitoneally with 1 g glucose/kg body weight, and blood glucose levels were determined at different time points.
As observed in
C. Increased Transgene Expression and Efficacy of Dual-Gene AAV1-miniCMV-Insulin-bGH(rev)-RSV-Glucokinase-SV40
C1. Generation of Optimized miniCMV-Insulin-bGH(rev)-RSV-Glucokinase-SV40 Dual-Gene AAV Constructs
Given that polyadenylation signals have been reported to influence transgene expression (Azzoni et al., J Gene Med 2007; 9: 392-40.), we generated a new dual-gene construct bearing the human insulin coding sequence under the control of the mini CMV promoter and the bGH polyA (expression cassette in reverse orientation) and the human glucokinase coding sequence driven by the RSV promoter and SV40 polyA (construct Q; same construct as L but with polyA signals interchanged). Two additional single-gene plasmids encoding insulin and glucokinase (constructs O and P, respectively) were generated using the same AAV backbone for comparison with the new dual-gene AAV1-Ins+Gck (Q) construct (
Construct O is depicted in
Construct P is depicted in
Construct Q is depicted in
C.2. Increased Transgene Expression In Vivo
Two groups of wild type mice were treated with either the 2 single vectors together (constructs O+P) (AAV1-miniCMV-hIns-bGH and AAV1-RSV-hGck-SV40) or with the dual gene (construct Q) (AAV1-miniCMV-Insulin-bGH(rev)-RSV-Glucokinase-SV40). Vectors were administered intramuscularly into tibialis and gastrocnemius muscles of both hindlimbs at a dose of 5E10 vg/muscle of each vector (constructs O and P or Q).
Three weeks after vector administration, animals were sacrificed and the expression of both transgenes (insulin and glucokinase) was analysed by real time quantitative PCR in the different experimental groups. We observed that the expression of both Insulin (
C.3. Increased Efficacy In Vivo
To demonstrate the efficacy of the newly designed Q dual-gene construct (AAV1-miniCMV-Insulin-bGH(rev)-RSV-Glucokinase-SV40), the ability of the vector to enhance glucose disposal in vivo was assessed in the experimental groups previously described in section C.2. To this end, a glucose tolerance test was performed in which all groups of mice were injected intraperitoneally with 2 g glucose/kg body weight, and blood glucose levels were determined at different time points.
As observed in
D. Increased Transgene Expression and Efficacy of Dual-Gene AAV1-miniCMV-hIns-SV40enhancer(Rev)-RSV-hGck-bGH
D.1. Generation of Optimized miniCMV-Insulin-SV40enhancer-RSV-Glucokinase-bGH Dual-Gene AAV Constructs
In order to increase the expression levels of insulin, the enhancer of the SV40 was incorporated at the 3′ end of the polyA. A new dual-gene construct bearing the human insulin coding sequence under the control of the mini CMV promoter and the SV40 enhancer at the 3′ end of the SV40 polyA (expression cassette in reverse orientation) and the human glucokinase coding sequence driven by the RSV promoter and the bGH polyA (construct S) was generated (
Construct R is depicted in
Construct S is depicted in
D.2. Increased Transgene Expression In Vivo
Two groups of wild type mice were treated with either the 2 single vectors together (constructs R+I) (AAV1-miniCMV-hIns-SV40enhancer and AAV1-RSV-hGck) or with the dual gene (construct S) (AAV1-miniCMV-hIns-SV40enhancer(rev)-RSV-hGck-bGH). Vectors were administered intramuscularly into tibialis and gastrocnemius muscles of both hindlimbs at a dose of 5E10 vg/muscle of each vector (constructs R and I or S).
Three weeks after vector administration, animals were sacrificed and the expression of both transgenes (insulin and glucokinase) was analysed by real time quantitative PCR in the different experimental groups. We observed that the expression of both Insulin (
D.3. Increased Efficacy In Vivo
To demonstrate the efficacy of the newly designed S dual-gene construct (AAV1-miniCMV-hIns-SV40enhancer(rev)-RSV-hGck-bGH), the ability of the vector to enhance glucose disposal in vivo was assessed in the experimental groups previously described in section D.2. To this end, a glucose tolerance test was performed in which all groups of mice were injected intraperitoneally with 2 g glucose/kg body weight, and blood glucose levels were determined at different time points.
As observed in
In conclusion, we believe the new approach based on the use of the dual-gene AAV1-INS-Gck vector allows for more—or at least the same—expression of therapeutic transgenes at considerably lower vector doses (half the vector genomes in dual-gene-treated mice), when compared to the combination of the two single vectors.
As the actions of insulin and glucokinase are synergic to create a glucose sensor in muscle, the use of dual-gene vectors allows the delivery of adequate amounts of both transgenes to the same cell. Therefore, the new approach based on the use of the dual-gene viral vector improves glucose metabolization to a higher extent when compared to the combination of the two single vectors. Moreover, it also allows for higher levels of expression of the transgenes using half the dose of viral genomes.
A: RSV-rGck-CMV-hIns (SEQ ID NO:8;
ITR 5′: 5585-5720 bp
CMV promoter: 22-1043 bp
hIns: 1120-1466 bp
SV40 polyA: 1532-1754
ITR 3′: 1821-1971 bp
B: CMV-hIns (SEQ ID NO:17;
ITR 5′: 1-136 bp
CMV promoter: 206-1227 bp
hIns: 1304-1650
SV40 polyA: 1752-1974 bp
ITR 3′: 2041-2191 bp
C: RSV-rGck (SEQ ID NO:18;
ITR 5′: 3802-3937 bp
RSV promoter: 4088-4803 bp
rGck: 4915-6292 bp
SV40 polyA: 6456-6694 bp
ITR 3′: 38-188 bp
D: CMV-hIns-RSV-hGck (SEQ ID NO: 9;
ITR 5′: 1-141 bp
CMV promoter: 193-1310 bp
hIns: 1318-1664 bp
SV40 polyA: 1678-1976 bp
RSV promoter: 2092-2801 bp
hGck: 2826-4240 bp
bGH polyA: 4248-4506 bp
ITR 3′: 4523-4663 bp
E: RSV-hGck-CMV-hIns (SEQ ID NO:10;
ITR 5′: 1-141 bp
RSV promoter: 239-948 bp
hGck: 973-2387 bp
bGH polyA: 2395-2653 bp
CMV promoter: 2698-3815 bp
hIns: 3823-4169 bp
SV40 polyA: 4183-4481 bp
ITR 3′: 4523-4663 bp
F: CMV-hIns(rev)-RSV-hGck (SEQ ID NO: 11;
ITR 5′: 1-141 bp
SV40 polyA: 182-480 bp
hIns: 494-840 bp
CMV promoter: 4248-1965 bp
RSV promoter: 2092-2801 bp
hGck: 2826-4240 bp
bGH polyA: 4248-4506 bp
ITR 3′: 4523-4663 bp
G; RSV-hGck-CMV-hIns(rev) (SEQ ID NO:12;
ITR 5′: 1-141 bp
RSV promoter: 239-948 bp
hGck: 973-2387 bp
bGH polyA: 2395-2653 bp
SV40 polya: 2687-2985 bp hIns: 2999-3345 bp
CMV promoter: 3353-4470 bp
ITR 3′: 4523-4663 bp
H: CMV-hIns (SEQ ID NO: 19;
ITR 5′: 1-141 bp
CMV promoter: 193-1310 bp
hIns: 1318-1664 bp
SV40 polyA: 1678-1976 bp
ITR 3′: 2018-2158 bp
I: RSV-hGck (SEQ ID NO: 20;
ITR 5′: 1-141 bp
RSV promoter: 239-948 bp
hGck: 973-2387 bp
bGH polyA: 2395-2653 bp
ITR 3′: 2670-2810 bp
J: miniCMV-hIns-RSV-hGck (SEQ ID NO: 13;
K: RSV-hGck-miniCMV-hIns (SEQ ID NO: 14;
ITR 5′: 1-141 bp
RSV promoter: 239-948 bp
hGck: 973-2387 bp
bGH polyA: 2395-2653 bp
miniCMV promoter: 2661-3071 bp
hIns: 3085-3431 bp
SV40 polyA: 3445-3743 bp
ITR 3′: 3785-3925 bp
L: miniCMV-hIns(rev)-RSV-hGck (SEQ ID NO: 15;
ITR 5′: 1-141 bp
SV40 polyA: 182-480 bp
hIns: 494-840 bp
miniCMV promoter: 854-1264 bp
RSV promoter: 1354-2063 bp
hGck: 2088-3502 bp
bGH polyA: 3510-3768 bp
ITR 3′: 3785-3925 bp
M: RSV-hGck-miniCMV-hIns(rev) (SEQ ID NO: 16;
ITR 5′: 1-141 bp
RSV promoter: 239-948 bp
hGck: 973-2387 bp
bGH polyA: 2395-2653 bp
SV40 polyA: 2687-2985 bp
hIns: 2999-3345 bp
miniCMV promoter: 3359-3769 pb
ITR 3′: 3785-3925 bp
N: miniCMV-hIns (SEQ ID NO: 21;
ITR 5′: 1-141 bp
miniCMV promoter: 156-566 bp
hIns: 580-926 bp
SV40 polyA: 940-1238 bp
ITR 3′: 1280-1420 bp
O: miniCMV-hIns-bGH (SEQ ID NO: 25;
ITR 5′: 2777-2917 bp
miniCMV promoter: 2932-3342 bp
hIns: 3356-3702 bp
bGH polyA: 3719-3971 bp
ITR 3′: 39-179 bp
P: RSV-hGck-SV40 (SEQ ID NO: 26;
ITR 5′: 2758-2898 bp
RSV promoter: 2996-3705 bp
hGck: 3730-5144 bp
SV40 polyA: 5155-5450 bp
ITR 3′: 20-160 bp
Q: miniCMV-hIns-bGH(rev)-RSV-hGck-SV40 (SEQ ID NO: 27;
ITR 5′: 5302-5442 bp
miniCMV promoter: 6109-6519 bp
hIns: 5749-6095 bp
bGH polyA: 5480-5732 bp
RSV promoter: 87-796 bp
hGck: 821-2235 bp
SV40 polyA: 2246-2541 bp
ITR 3′: 2564-2704 bp
R: miniCMV-hIns-SV40enhancer (SEQ ID NO: 28;
ITR 5′: 2777-2917 bp
miniCMV promoter: 2932-3342 bp
hIns: 3356-3702 bp
SV40 enhancer and SV40 polyA: 3719-4238 bp
ITR 3′: 39-179 bp
S: miniCMV-hIns-SV40enhancer(rev)-RSV-hGck-bGH (SEQ ID NO: 29;
pAAV-miniCMV-hIns-SV40enhancer(rev)-RSV-hGck-bGH Plasmid Sequence
ITR 5′: 5256-5396 bp
miniCMV promoter: 6330-6740 bp
hIns: 5970-6316 bp
SV40 enhancer and SV40 polyA: 5434-5953 bp
RSV promoter: 87-796 bp
hGck: 821-2235 bp
bGH polyA: 2243-2501 bp
ITR 3′: 2518-2658 bp
| Number | Date | Country | Kind |
|---|---|---|---|
| 15150376 | Jan 2015 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2016/050147 | 1/7/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2016/110518 | 7/14/2016 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5139941 | Muzyczka et al. | Aug 1992 | A |
| 5436146 | Shenk et al. | Jul 1995 | A |
| 5446143 | Simpson et al. | Aug 1995 | A |
| 5464758 | Gossen et al. | Nov 1995 | A |
| 5478745 | Samulski et al. | Dec 1995 | A |
| 5741683 | Zhou et al. | Apr 1998 | A |
| 5858351 | Podsakoff et al. | Jan 1999 | A |
| 5891717 | Newgard | Apr 1999 | A |
| 6001650 | Colosi | Dec 1999 | A |
| 6057152 | Samulski et al. | May 2000 | A |
| 6136597 | Hope et al. | Oct 2000 | A |
| 6156303 | Russell et al. | Dec 2000 | A |
| 6165782 | Naldini et al. | Dec 2000 | A |
| 6204059 | Samulski et al. | Mar 2001 | B1 |
| 6207455 | Chang | Mar 2001 | B1 |
| 6211163 | Podsakoff et al. | Apr 2001 | B1 |
| 6218181 | Verma et al. | Apr 2001 | B1 |
| 6258595 | Gao et al. | Jul 2001 | B1 |
| 6268213 | Samulski et al. | Jul 2001 | B1 |
| 6277633 | Olsen | Aug 2001 | B1 |
| 6323031 | Cichutek | Nov 2001 | B1 |
| 6325998 | Podsakoff et al. | Dec 2001 | B1 |
| 6358732 | Sedlacek et al. | Mar 2002 | B1 |
| 6391858 | Podsakoff et al. | May 2002 | B2 |
| 6432705 | Yee et al. | Aug 2002 | B1 |
| 6491907 | Rabinowitz et al. | Dec 2002 | B1 |
| 6531456 | Kurtzman et al. | Mar 2003 | B1 |
| 6596535 | Carter | Jul 2003 | B1 |
| 6642051 | Lynch et al. | Nov 2003 | B1 |
| 6660514 | Zolotukhin et al. | Dec 2003 | B1 |
| 6893867 | Webster | May 2005 | B1 |
| 6951753 | Shenk et al. | Oct 2005 | B2 |
| 7056202 | Pein | Jun 2006 | B2 |
| 7056502 | Hildinger et al. | Jun 2006 | B2 |
| 7091029 | Hwang | Aug 2006 | B2 |
| 7094604 | Snyder et al. | Aug 2006 | B2 |
| 7125717 | Carter | Oct 2006 | B2 |
| 7172893 | Rabinowitz et al. | Feb 2007 | B2 |
| 7198951 | Gao et al. | Apr 2007 | B2 |
| 7201898 | Monahan et al. | Apr 2007 | B2 |
| 7220577 | Zolotukhin | May 2007 | B2 |
| 7229823 | Samulski et al. | Jun 2007 | B2 |
| 7235393 | Gao et al. | Jun 2007 | B2 |
| 7238674 | Podsakoff et al. | Jul 2007 | B2 |
| 7250406 | Tang et al. | Jul 2007 | B2 |
| 7282199 | Gao et al. | Oct 2007 | B2 |
| 7319002 | Wilson et al. | Jan 2008 | B2 |
| 7425443 | Alam et al. | Sep 2008 | B2 |
| 7439065 | Ferrari et al. | Oct 2008 | B2 |
| 7456683 | Takano et al. | Nov 2008 | B2 |
| 7790449 | Gao et al. | Sep 2010 | B2 |
| 8556842 | Bridges et al. | Oct 2013 | B2 |
| 8865881 | Balazs et al. | Oct 2014 | B2 |
| 9309534 | Bosch Tubert et al. | Apr 2016 | B2 |
| 9365829 | Simpson | Jun 2016 | B2 |
| 9527904 | Balazs et al. | Dec 2016 | B2 |
| 9732329 | Simpson et al. | Aug 2017 | B2 |
| 10426845 | Nathwani et al. | Oct 2019 | B2 |
| 20020065239 | Caplan et al. | May 2002 | A1 |
| 20030138772 | Gao et al. | Jul 2003 | A1 |
| 20030148506 | Kotin et al. | Aug 2003 | A1 |
| 20030219409 | Coffin et al. | Nov 2003 | A1 |
| 20040055023 | Bosch Tubert et al. | Mar 2004 | A1 |
| 20050187154 | Kahn et al. | Aug 2005 | A1 |
| 20080075740 | Gao et al. | Mar 2008 | A1 |
| 20100216709 | Scheule et al. | Aug 2010 | A1 |
| 20100240029 | Guarente et al. | Sep 2010 | A1 |
| 20110166210 | Felber et al. | Jul 2011 | A1 |
| 20120040401 | Ellis | Feb 2012 | A1 |
| 20140194352 | Ling et al. | Jul 2014 | A1 |
| Number | Date | Country |
|---|---|---|
| 2394667 | Dec 2011 | EP |
| 2492347 | Aug 2012 | EP |
| 2692868 | Feb 2014 | EP |
| 3101125 | Dec 2016 | EP |
| 1998009524 | Mar 1998 | WO |
| 1998011244 | Mar 1998 | WO |
| WO-199832869 | Jul 1998 | WO |
| 1999061601 | Dec 1999 | WO |
| 2000028004 | May 2000 | WO |
| 2000028061 | May 2000 | WO |
| 2010010887 | Jan 2001 | WO |
| 2001083692 | Nov 2001 | WO |
| 2001094605 | Dec 2001 | WO |
| 2002024234 | Mar 2002 | WO |
| 2002049423 | Jun 2002 | WO |
| WO-200249423 | Jun 2002 | WO |
| 2003042397 | May 2003 | WO |
| 2003052051 | Jun 2003 | WO |
| 2003052052 | Jun 2003 | WO |
| 2005033321 | Apr 2005 | WO |
| WO-2006110689 | Oct 2006 | WO |
| WO-2008027084 | Mar 2008 | WO |
| 2008071959 | Jun 2008 | WO |
| WO-2009151172 | Dec 2009 | WO |
| WO 2009151172 | Dec 2009 | WO |
| WO-2011004051 | Jan 2011 | WO |
| WO2011154520 | Dec 2011 | WO |
| 2012007458 | Jan 2012 | WO |
| 2012007458 | Jan 2012 | WO |
| 2013033452 | Mar 2013 | WO |
| 2014020149 | Feb 2014 | WO |
| WO-2014020149 | Feb 2014 | WO |
| 2015044292 | Apr 2015 | WO |
| 2015060722 | Apr 2015 | WO |
| 2015173308 | May 2015 | WO |
| WO2015173308 | Nov 2015 | WO |
| 2016041588 | Mar 2016 | WO |
| 2016087678 | Jun 2016 | WO |
| 2016110518 | Jul 2016 | WO |
| WO2016193431 | Dec 2016 | WO |
| WO2018060097 | Apr 2018 | WO |
| WO-2018060097 | Apr 2018 | WO |
| Entry |
|---|
| Li et al. A small regulatory elemnt from chromosome 19 enhances liver-specific gene expression. Gene Therapy 16:43-51, 2009. |
| Zarrin et al. Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochimica et Biophysica Acta 1446:135-139, (Year: 1999). |
| Boulos et al. Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures. Brain Research 1102:27-38, (Year: 2006). |
| Liu et al. Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. Experimental and Molecular Medicine 39:170-175, (Year: 2007). |
| Tian J et al. Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector. Gene Therapy 16:874-884, (Year: 2009). |
| Fagoe ND et al. A compact dual promoter adeno-assoicated viral vector for efficient delivery of two genes to dorsal root ganglion neurons. Gene Therapy 21:242-252, (Year: 2014). |
| Callejas, D., et al., “Treatment of Diabetes and Long-Term Survival After Insulin and Glucokinase Gene Therapy,” Diabetes, vol. 62, No. 5, pp. 1718-1729 (May 1, 2013). |
| Tae Keun Oh, et al., “Gene Therapy for Diabetes Mellitus in Rats by Intramuscular Injection of Lentivirus Containing Insulin Gene,” Diabetes Research and Clinical Practice, vol. 71, No. 3, pp. 233-240 (Mar. 1, 2006). |
| Kamata, K., et al., “Structural Basis for Allosteric Regulation of the Monomeric Allosteric Enzyme Human Glucokinase,” Structure, vol. 12, pp. 429-438 (Mar. 2004). |
| Smith, G. David., et al., “The Structure of T6 Human Insulin at 1.0 A Resolution,” Acta Crystallographica Section D, Biological Crystallography, Research Papers, D59, pp. 474-482 (2003). |
| Monahan P et al, AAV vectors: is clinical success on the horizon?, Gene Therapy, vol. 7, pp. 24-30, Jan. 17, 2000. |
| Chao et al, Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Molecular Therapy vol. 2(6):619-623, 2000. |
| Ahi et al, Adenoviral Vector Immunity: Its implications and circumvention strategies. Curr. Gene Ther. vol. 11(4), pp. 307-320, 08.2011. |
| Azzoni AR, The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression. J Gene Med, vol. 9(5), pp. 392-402, 2007. |
| Ai-Dossari Mohammad et al, Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochemical and Biophysical Research Communications vol. 339(2), pp. 673-678, Jan. 13, 2006. |
| Alexopoulou et al, The CMV earlyenhancer/chicken beta actin (CAG) promoter can be used to drive transgene expressionduring the differentiation of murine embryonic stem cells into vascular progenitors. Bmc Cell Biol. vol. 9(2), pp., Jan. 11, 2008. |
| Bish L, et aL, Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat. Hum. Gene Ther. vol. 19(12), pp. 1359-1368, 2008. |
| Boshart M, et al., Cell, 1985, A very strong enhancer is located upstream of an immediate early gene of human aytomegalovirus, vol. 41, pp. 521-530, Jun. 1, 1985. |
| Boulos et al, Assessment of CMV, RSV and SYN1 promoters and the woodchuck post-transcriptional regulatory element in adenovirus vectors for transgene expression in cortical neuronal cultures. Brain Research vol. 1102, pp. 27-38, 2006. |
| Callejas et al, Gene Therapy for Type I Diabetes by Engineering Skeletal Muscle to Express Insulin and Glucokinase (GK): Pre-clinical studies in Diabetic Dogs. Poster presentation, 2007. |
| Callejas et al, Gene Therapy for Type I Diabetes by Engineering Skeletal Muscle to Express Insulin and Glucokinase (GK): Pre-clinical studies in Diabetic Dogs. Poster presentation, 2008. |
| Carter and Samulski, Adeno-associated viral vectors as gene delivery vehicles. Int. J. Mol. Med. vol. 6, pp. 17-27, 2000. |
| Chiorini et al., Cloning and characterization of adeno-associated virus type 5., J . of Virology, vol. 73(2), pp. 1309-1319, Feb. 1, 1999. |
| Croyle M, et al., Development of Novel Formulations That Enhance Adenoviral-Mediated Gene Expression in the Lung in Vitro and in Vivo. Mol. Ther. vol. 4, pp. 22-28, 2001. |
| Donello J, et al., Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element, J. Virol. 1998, vol. 72(6), pp. 5085-5092 ,Jun. 1998. |
| F-L Zhang et al, Celastrol enhances AAV1-mediated gene expression in mice adipose tissues. Gene Therapy vol. 18 (2), pp. 128-134, Jan. 2, 2011. |
| Gao et al, Clades of Adeno-associated viruses are widely disseminated in human tissues. J. Virol. vol. 78, pp. 3381-6388, 2004. |
| Gao et al, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. PNAS vol. 99, pp. 11854-11859, 2002. |
| Jimenez et al, in vivo genetic engineering of murine pancreatic beta cells mediated by single-stranded adeno-associated viral vectors of serotypes 6, 8 and 9. Diabetologia ; Clinical and Experimental, Diabetes and Metabolism, Springer, Berlin, DE, vol. 54(5), pp. 1075-1086, Nov. 2, 2011. |
| Kapturczak et al., Transduction of Human and Mouse Pancreatic Islet Cells Using a Bicistronic Recombinant Adeno-associated Viral Vector. Molecular Therapy vol. 5(2), pp. 154-160, Feb. 2002. |
| Kitajima et al, Persistent liver expression of murine apoA-I using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis vol. 186, pp. 65-73, 2006. |
| Larose M, et al., Essential cis-Acting Elements in Rat Uncoupling Protein Gene Are in an Enhancer Containing a complex Retinoic Acid Response Domain. J. Biol. Chem. 1996; 271(49):31533-31542, 1996. |
| Lebherz C, et al.,Novel Aav serotypes for improved ocular gene transfer. J. Gene Med. vol. 10, pp. 375-382, 2008. |
| Lee et al, Optimizing regulatable gene expression using adenoviral vectors. Experimental Physiology vol. 90, pp. 33-37, 2004. |
| Li et al, a small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Therapy 16, pp. 43-51, 2009. |
| Liu et al, Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. Experimental and Molecular Medicine vol. 39, pp. 170-75, 2007. |
| Lock et al, Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum. Gene Ther. vol. 21, pp. 1273-1285, 2010. |
| Loiler et al, Localized gene expression following administration of adeno-associated viral vectors via pancreatic lucts. Mot Ther. vol. 12, pp. 519-527, 2005. |
| Moris et al, Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology vol. 330, pp. 375-383, 2004. |
| Nakai H, et al., Unrestricted Hepatocyte Transduction with Adeno-Associated VirusSerotype 8 Vectors in Mice. J. Virol. vol. 79, pp. 214-224, 2005. |
| Okada T et al, Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes., Hum. Gene Ther., vol. 20, pp. :1013-1021, Aug. 5, 2009. |
| Otaegui et al, Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice. The FASEB Journal express article. Online 10.1096M.03-0081fje,18.09.2003. |
| Pacak C, et al.,Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction in Vivo. Circ. Res. vol. 99:e3-e9, 2006. |
| Qiao C et al, Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver, Gene Therapy vol. 18(4), pp. 403-410, Jan. 4, 2011. |
| Rabinowitz J et al, Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity, vol. 76(2), pp. 791-801, Jan. 2002. |
| Rehman et al, Efficient gene delivery to human and rodent islets with doublestranded (ds) AAV-based vectors. Gene Therapy, vol. 12(17), pp. 1313-23, 2005. |
| Smith T.J, Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune Diseases? Pharmacol. Rev. vol. 62, pp. 199-236, 2010. |
| Taymans J, et al., Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. vol. 18, pp. 195-206, 2007. |
| Tian et al, Independent and high-level dual-gene expression in adult stem-progenitor cells from a single lentiviral vector. Gene Therapy vol. 16, pp. 874-884, 2009. |
| Urabe et al, a novel dicistronic AAV vector using a short Ires segment derived from hepatitis C virus genome. Gene vol. 200, pp. 157-62, 1997. |
| Vila GBP et al, 237: AAV8-mediated Sirt1 overexpression in the liver prevents high-carbohydrate diet induced NAFLD. Diabetologia, 49th Annual Meeting of the European Association for the Study of Diabetes, Springer, Berlin, DE; Barcelona, Spain, vol. 56, Suppl. 1, p. S105, 27.09.2013. |
| Wang et al, Improved neuronal transgene expression from an AAV-2 vector with a hybrid Cmv enhancer/PDGF-βpromoter, J Gene Med., vol. 7, pp. 945-955, Mar. 9, 2005. |
| Mao et al, Gene therapy vectors based on adeno-associated virus type 1. J. Virology vol. 73:3994, 1999. |
| Yan et al, Inverted Terminal Repeat Sequences are Important for Intermolecular Recombination and Circularization of Adeno-Associated Virus Genomes. Journal of Virology, vol. 79, pp. 364-379, 2005. |
| Zarrin et al, Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines. Biochimica and Physica Acta vol. 1446, pp. 135-139, 1999. |
| Zincarelli et al, Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic Injection. Mol Ther vol. 16(6), pp. 1073-80, 2008. |
| Zufferey R, et al.,Woodchuck hepatitis virus post transcriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. vol. 73, pp. 2886-2892, 1999. |
| Chlorini et al, Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Vir. vol. 71, pp. 6823-33, 1998. |
| Mann et al, Gene therapy for type 1 diabetes by engineering skeletal muscle to express insulin and glucokinase (GK):Pre-clinical studies in diabetic. Diabetes (online), pp. A125-A126, 01.06.2008. |
| Dressman D., AAV-Mediated Gene Transfer to Models of Muscular Dystrophy: Insights into Assembly of Multi-Subunit Membrane Proteins. University of Pittsburgh, Graduate Faculty of the School of Medicine, Dept. Of Biochemistry and Molecular Genetics in partial fulfillment of the requirements for the degree of Doctor of Philosophy. 183 pp.,1997. |
| Mas et al., Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle. Diabetes vol. 55(6), pp. 1546-53, Jun. 2006. |
| Jimenez-Chillaron et al., Increased glucose disposal induced by adenovirus-mediated transfer of glucokinase to skeletal muscle in vivo. Faseb J vol. 13, pp. 2153-2160, 1999. |
| Otaegui et al., Glucose-regulated glucose uptake by transplanted muscle cells expressing glucokinase counteracts liabetic hyperglycemia. Hum Gene Ther vol. 13, pp. 2125-2133, 2002. |
| Tae Keun Oh et al, Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. Diabetes Research and Clinical Practice vol. 71(3), pp. 233-40 Jan. 3, 2006. |
| Lukashev et al. Viral Vectors for Gene Therapy: Current State and Clinical Perspectives. Bioschemistry (Mosc) vol. 31(7), pp. 700-708, 2016. |
| Mas, A., et al., “Reversal of type 1 diabetes by engineering a glucose sensor in skeletal muscle,” Diabetes 55(6):1546-53, American Diabetes Association Inc., United States (2006). |
| Otaegui, P.J., et al., “Glucose-regulated glucose uptake by transplanted muscle cells expressing glucokinase counteracts diabetic hyperglycemia,” Hum Gene Ther 13(18):2125-2133, Mary Ann Liebert Inc., United States (2002). |
| Fagoe, N.D., et al., “A compact dural promoter adeno-associated viral vector for efficient delivery of two genes to dorsal root ganglion neurons,” Gene Ther. 21:242-252, Nature Publishing Group, United Kingdom (2014). |
| American Diabetes Association, “Diagnosis and Classification of Diabetes Mellitus,” Diabetes Care 33(Suppl 1):S62-69, American Diabetes Association, United States (2010). |
| Bergerot, I., et al., “Effects of insulin like growth factor-1 and insulin on effector T cells generating autoimmunie diabetes,” Diabetes Metab. 22(4):235-239, Elsevier Masson, France (1996). |
| Daya, S., et al., “Gene therapy using adeno-associated virus vectors,” Clinical Microbiology Reviews 21(4):583-593, American Society of Microbiology, United States (2008). |
| Gros, L., et al., “Insulin Production By Engineered Muscle Cells,” Human Gene Therapy 10(7):1207-1217, Mary Ann Liebert, Inc., United States (1999). |
| Gros L., et al., “Regulated Production of Mature Insulin by Non-beta Cells,” Human Gene Therapy 8(18):2249-2259, Mary Ann Liebert Inc., United States (1997). |
| Hafenrichter, D.G., et al., “Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes,” Blood 84:3394-3404, American Society of Hematology, United States (1994). |
| Haurigot, V., et al., “Future Directions: Gene Therapy For Diabetes,” Part 13, Ch. 70, in Textbook of Diabetes, 5th Edition, Holt, R., et al., eds., pp. 1029-1037, Wiley-Blackwell, United States (2017). |
| Jaen, M.L., et al., “Long-Term Efficacy And Safety Of Insulin And Glucokinase Gene Therapy For Diabetes: 8-Year Follow-Up In Dogs,” Molecular Therapy—Methods & Clinical Development 6:1-7, Elsevier, Netherlands (2017). |
| Kapturczak, M., et al., “Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector,” Molecular Therapy 5(2):154-160, Cell Press, United States (2002). |
| Lee, H.C., et al., “Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue,” Nature 408:483-488, Nature Publishing Group, United Kingdon (2000). |
| Mann, C.J., et al., “Gene therapy for type 1 diabetes by expressing insulin and glucokinase (GK) in skeletal muscle; pre-clinical studies in diabetic dogs,” Molecular Therapy /6(Supplement_1):5367, Cell Press, United States (2008). |
| Mann, C.J., et al., “Molecular Signature of the Immune and Tissue Response to Non-Coding Plasmid Dna in Skeletal Muscle After Electrotransfer,” Gene Therapy /9(12):1177-1186, Macmillan Publishers Limited, United States (2012). |
| Mann, C.J., et al., “Skeletal Muscle Metabolism in the Pathology and Treatment of Type 1 Diabetes,” Current Pharmaceutical Design 16(8):1002-1020, Bentham Science Publishers Ltd., Netherlands (2010). |
| Mann, C.J., et al., “Gene therapy for type 1 diabetes by engineering skeletal muscle to express insulin and glucokinase (GK): Pre-clinical studies in diabetic dogs,” Diabetes — American Diabetes Association 68' Scientific Sessions: Abstract 420-P, pp. A125-A126, United States (Jun. 2008). Accessed at http://diabetes.diabetesjournals.org. |
| Matschinsky, M.F., “Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm,” Diabetes 45(2):223-241, American Diabetes Association, Inc., United States (1996). |
| O'Brien, T., “Gene Therapy for Type 1 Diabetes Moves a Step Closer to Reality,” Diabetes 62(5):1396-1397, American Diabetes Association, United States (2013). |
| Oh, T.K., et al., “Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene,” Diabetes Research and Clinical Practice 71(3):233- 240, Elsevier Ireland Ltd., Ireland (2006). |
| Otaegui, P., et al., “Expression of Glucokinase in Skeletal Muscle: a New Approach to Counteract Diabetic Hyperglycemia,” Human Gene Therapy 11(11):1543-1552, Mary Ann Liebert, Inc., United States (2000). |
| Printz, R.L., et al., “Mammalian glucokinase,” Annu Rev Nutr 13:463-496, Annual Reviews Inc., United States (1993). |
| Sharp, P.M., and Li, W-H., “The codon adaptation index - a measure of directional synonymous codon usage bias, and its potential applications,” Nucleic Acids Res. 15(3):1281-1295, Oxford University Press, United Kingdom (1987). |
| Zarrin, A.A., et al., “Comparison of CMV, RSV, SV40 viral and Vlambda1 cellular promoters in B and T lymphoid and non-lymphoid cell lines,” Biochim Biophys Acta 1446(1-2):135-139, Elsevier, Netherlands (1999). |
| Anguela, X.M. et al., “Nonviral-Mediated Hepatic Expression of IGF-I Increases Treg Levels and Suppresses Autoimmune Diabetes in Mice,” Diabetes, 62(2): 551-560, The American Diabetes Association, United States (2013). |
| Ayuso, E., and Bosch, F., “Highlights On AAV Mediated Gene Transfer: Introduction,” in The Clinibook: Clinical Gene Transfer State Of The Art, Cohen-Haguenauer, O., ed., pp. 31-34, Éditions EDK, Paris (2012). |
| Ayuso, E., et al., “AAV Gene Therapy For Diabetes Mellitus,” in The Clinibook: Clinical Gene Transfer State of the Art, Cohen-Haguenauer, O., ed., pp. 62-70, Éditions EDK, Paris (2012). |
| Ayuso, E., et al., “Reference Materials for the Characterization of Adeno-Associated Viral Vectors,” in The Clinibook: Clinical Gene Transfer State of the Art, Cohen-Haguenauer, O., ed., pp. 83-90, Éditions EDK, Paris (2012). |
| Ayuso, E., et al., “High AAV vector purity results in serotype- and tissue- independent enhancement of transduction effiiency,” Gene Therapy, 17(4):503-10, Macmillan Publishers Limited, United States (2010). |
| Ayuso, E., et al., “Production, Purification and Characterization of Adeno-Associated Vectors,” Current Gene Therapy, 10(6): 423-426, Bentham Science Publishers Ltd., Netherlands (2010). |
| Fagoe, ND., “A compact dual promoter adeno-associated viral vector for effiient delivery of two genes to dorsal root ganglion neurons,” Gene Therapy, 21: 242-252, Macmillan Publishers Limited, United States (2014). |
| Garcia, M., et al., “Phosphofructo-1-Kinase Deficiency Leads To A Severe Cardiac And Hematological Disorder In Addition To Skeletal Muscle Glycogenosis,” PLoS Genetics, 5(8): e1000615, pp. 1-12, Public Library of Science, United States (2009). |
| Gros, L., et al., “Insulin Production By Engineered Muscle Cells,” Human Gene Therapy. 10:1207-1217, Mary Ann Liebert, Inc., United States (1999). |
| Haurigot, V., et al., “Future Directions: Gene Therapy For Diabetes,” Part 13, Ch. 70, in Textbook of Diabetes, 5th Edition, Holt, R., et al., edds., pp. 1029-1037, Wiley-Blackwell, United States (2017). |
| Mann, C.J., et al., “Molecular Signature Of The Immune And Tissue Response To Non-Coding Plasmid DNA In Skeletal Muscle After Electrotransfer,” Gene Therapy 19(12):1177-1186, Macmillan Publishers Limited, United States (2012). |
| Otaegui, P., et al., “Expression Of Glucokinase In Skeletal Muscle: A New Approach To Counteract Diabetic Hyperglycemia,” Human Gene Therapy, 11: 1543-1552, Mary Ann Liebert, Inc., United States (2000). |
| Riu, E., et al., “Counteraction Of Type 1 Diabetic Alterations By Engineering Skeletal Muscle to Produce Insulin, Insights From Transgenic Mice,” Diabetes, 51:704-711, American Diabetes Association (2002). |
| Vilà, L. et al., Aav-mediated Sirt1 Overexpression In Skeletal Muscle Activates Oxidative Capacity But Does Not Prevent Insulin Resistance. Molecular Therapy-Methods & Clinical Development, 5:16072, eCollection (Nov. 2016). |
| Number | Date | Country | |
|---|---|---|---|
| 20180000967 A1 | Jan 2018 | US |
